According to Zacks Investment Research, Rewalk reported revenue of $1.2 million for a a loss of $3.9 million for Q4, 2021. It also reported $6 million of revenue for the year with a loss of $12.7 million, or 27 cents per share. See https://www.zacks.com/ap/RWLK for details.
ReWalk Robotics Completes One-for-Twenty-Five Reverse Share Split
The reverse split will take effect tomorrow, April 1. As a result of the reverse share split, every twenty-five ordinary shares of ReWalk issued and outstanding were automatically combined and reclassified into one ordinary share of ReWalk. Appropriate adjustments were also made to all outstanding derivative securities of the Company, including all outstanding equity awards and warrants.
ReWalk places 500th spinal cord system
With 38 different payers in the U.S. and 39 in Germany that provide positive coverage for individual system procurements, Rewalk recently placed its 500th medical device for patients with spinal cord injuries.
Correcting and Updating: ReWalk's Restore technology for stroke patients featured in MD&DI
ReWalk Robotics' (Nasdaq: RWLK) ("ReWalk" or the "Company") innovative Restore soft exoskeleton system was featured in a recent story as one of the cutting edge technologies seeking to help stroke survivors heal and retain critical motor skills. The story published in Medical Device & Diagnostic Industry (MD&DI), a leading industry trade magazine.